JPMorgan CEO sees expenses going up; shares slide

JPMorgan raised its full-year 2026 expense forecast to about $106 billion from $105 billion, implying costs could be $1 billion higher than earlier estimates and potentially pressuring profitability. Dimon also reiterated interest in acquisitions, saying the bank could allocate $10 billion to $20 billion for a deal over the next couple of years. Separately, he said Q2 investment banking fees could rise 10% or more and markets revenue is tracking up 11% for the quarter, but shares were down nearly 3% on concern about higher expenses.

Analysis

The market is likely conflating a higher expense guide with a slower earnings trajectory, but the more important signal is that JPM is still choosing to spend through the cycle. That typically widens the moat: the bank can absorb incremental tech, compliance, and talent spend while smaller peers are forced to defend margins or pull back, which should gradually reinforce share gains in payments, lending, and markets. The second-order effect is that higher industry spending raises the bar for fintech challengers and regional banks that lack JPM’s deposit base and scale economics.

The bigger near-term catalyst is not the cost line, but the operating leverage from capital markets reopening. If fee and trading momentum persists into the next two quarters, the incremental revenue can offset a meaningful chunk of the expense increase, making the guidance bump look more like investment than deterioration. That said, the market is paying a premium multiple for perceived durability; any sign that revenue normalization is arriving faster than expected would compress the stock in a hurry over the next 1-3 months.

The M&A commentary matters more for optionality than immediate earnings. A $10-$20B acquisition would likely be aimed at capability acquisition rather than balance-sheet expansion, which implies fintech, payments, wealth tech, or AI infrastructure; that would pressure vendors in those ecosystems while strengthening JPM’s distribution. The contrarian read is that the stock may be overreacting to the expense print because investors are missing the embedded call option on deal activity and cyclically stronger ECM/IB revenue, but the longer-duration risk is that management keeps signaling peak earnings rhetoric while the market still prices JPM like a compounder.

For the broader banking complex, this is mildly negative for scale-disadvantaged lenders and neutral-to-positive for capital markets names. If JPM’s spend discipline is still allowing it to grow above-plan, peers may need to defend share with higher comp and tech budgets into 2026, which compresses sector margins even if the macro stays supportive. The main tail risk is a sharp turn in deal activity or trading volatility normalization; either would expose that the current earnings strength is more cyclical than structural.

Key Decisions for Investors

• Short-term: buy JPM 1-2 month downside protection via put spreads into any post-earnings relief rally; risk/reward improves if the stock re-rates back toward premium valuation while expense skepticism lingers.
• Pair trade: long JPM / short KRE for 1-3 months to express the widening scale gap; JPM can absorb higher operating spend while regionals face margin pressure if deposit competition and tech spend stay elevated.
• Buy a basket of capital markets beneficiaries on a 3-6 month view, e.g. long JPM and GS, if ECM/IB momentum continues; upside comes from operating leverage, while the main risk is deal pipelines stalling.
• Fade fintech vendors exposed to in-house build risk with a relative-value short in a payments/AI infrastructure name versus JPM over 6-12 months; JPM’s potential acquisition path raises competitive pressure on outsourced solution providers.
• If JPM sells off >5% without a downgrade in revenue expectations, add long exposure; the expense guide alone is unlikely to impair ROE materially unless revenue momentum reverses, which is the key risk to monitor.